The Smartest Dividend Stocks to Buy With $5,000 Right Now

The article spotlights three cash-flow-rich dividend growers—Coca‑Cola, Merck and PepsiCo—as income-oriented ideas: Coca‑Cola (2.7% yield) has a 62‑year dividend growth streak, posted a 17% adjusted Q2 profit increase, and generated $3.3bn of FCF in H1 against $2.2bn of dividends; Merck (2.6% yield) is being driven by Keytruda (≈$25bn last year and 45% of Q2 sales), saw Q2 sales ex‑FX +11%, produced $7.1bn FCF in H1 versus $3.9bn of dividends and has pipeline/label approvals supporting growth; PepsiCo (3.1% yield) grew adjusted EPS 10% in Q2 despite 2% sales growth, raised its dividend 7% in April and has a 52‑year raise streak though its payout ratio (~73%) is relatively high. Together they offer durable dividends backed by strong cash flow and brand franchises, but investors should note Merck’s Keytruda concentration risk and PepsiCo’s elevated payout ratio as potential constraints on future flexibility.

Analysis

The article highlights three cash-flow-rich dividend growers—Coca-Cola (KO), Merck (MRK) and PepsiCo (PEP)—as income-oriented ideas, noting a moderately positive, defensive sentiment and limited market-impact signal. All three have long dividend-raising histories (Coca‑Cola 62 years, PepsiCo 52 years) and yields above the S&P 500 average (KO 2.7%, MRK 2.6%, PEP 3.1%), supporting an income-focused allocation.

Coca‑Cola reported a 17% adjusted profit gain in Q2 after FX adjustments, generated $3.3bn of free cash flow in H1 versus $2.2bn in dividends, and continues to expand sales and market share while covering payouts comfortably. The board raised the annual dividend to $1.94, underscoring steady cash conversion and payout sustainability at a 2.7% yield.

Merck is driven by Keytruda (about $25bn last year and ~45% of Q2 sales) and posted Q2 sales ex‑FX +11%, with H1 FCF of $7.1bn covering $3.9bn of dividends; recent approval of Winrevair and other pipeline assets support growth but concentrate risk in oncology. PepsiCo delivered Q2 adjusted EPS +10% despite only 2% sales growth, boosted a 7% dividend raise in April and yields 3.1%, yet carries a relatively high payout ratio (~73%), which could limit financial flexibility if top‑line pressure persists.

Key Decisions for Investors

• Consider overweighting Coca‑Cola for core dividend exposure given its 62‑year raise streak, strong H1 FCF ($3.3bn) and dividends well covered by cash flow
• Treat Merck as a selective buy/hold: its FCF coverage and Keytruda momentum support dividends but monitor concentration risk and upcoming pipeline/regulatory catalysts closely
• Approach PepsiCo with caution—the 3.1% yield and recent 7% raise are attractive, but a ~73% payout ratio argues for limiting position size or waiting for clearer sales volume recovery
• Monitor FX‑adjusted earnings, FCF trends and payout ratios across all three and be prepared to trim or hedge positions if cash flow coverage weakens or Keytruda/pipeline news materially alters Merck's outlook